KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Preferred Stock Liabilities (2018 - 2019)

Historic Preferred Stock Liabilities for Castle Biosciences (CSTL) over the last 2 years, with Q2 2019 value amounting to $45.1 million.

  • Castle Biosciences' Preferred Stock Liabilities changed N/A to $45.1 million in Q2 2019 from the same period last year, while for Jun 2019 it was $45.1 million, marking a year-over-year change of. This contributed to the annual value of $45.0 million for FY2018, which is N/A changed from last year.
  • Latest data reveals that Castle Biosciences reported Preferred Stock Liabilities of $45.1 million as of Q2 2019.
  • Castle Biosciences' Preferred Stock Liabilities' 5-year high stood at $45.1 million during Q2 2019, with a 5-year trough of $45.0 million in Q4 2018.